LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 31, 2024 | Last Trade: US$0.85 0.03 4.04

MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024.

Management will participate in a Fireside Chat on June 6th at 11:30 AM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications, This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations

Chris Calabrese, This email address is being protected from spambots. You need JavaScript enabled to view it. 

Kevin Gardner, This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page